Foley is pleased to sponsor the Michigan Legal Summit: Health Information and the Law – What’s Next? Hosted by Michigan Health Information Network, top legal experts from around the country will join us for a discussion on legal topics surrounding health information technology.
During this session, presenters will delve into developments in the Trusted Exchange Framework and Common Agreement, Bioethics in the Realm of Electronic Information Sharing, Common Conundrums in Healthcare Privacy and Consent, and more.
The following Foley attorneys will be presenting during the program:
- Foley partner Monica Chmielewski will present on Remote Medicine
- Foley partners Jennifer Belveal and Larry Vernaglia will present on Fraud, Abuse and Enforcement Actions
- Foley partner Larry Vernaglia will present on Bioethics and Health Information Sharing
- Foley partner Chanley Howell will present on Health Care Privacy and Electronic Consent
Click here to view the complete agenda and to register for the Legal Summit. For questions, please contact legalworkshop@mihin.org.
People
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.